{"id":428739,"date":"2026-04-22T09:26:00","date_gmt":"2026-04-22T01:26:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=428739"},"modified":"2026-04-22T09:26:00","modified_gmt":"2026-04-22T01:26:00","slug":"%e3%80%902026-asco%e3%80%91%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a0%85%e7%8d%b2%e5%bf%ab%e9%80%9f%e5%8f%a3","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=428739","title":{"rendered":"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde<\/span>2026\u5e744\u670822\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae<\/sup>\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae<\/sup>\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002<\/p>\n

\n<\/p><\/div>\n

\u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002<\/p>\n

\u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb<\/b>\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d<\/p>\n

\u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a<\/p>\n

\u5feb\u901f\u53e3\u982d\u5831\u544a<\/u><\/b><\/p>\n

Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
<\/b>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b>HQP1351<\/b>\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08<\/b>CML-LBP<\/b>\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027<\/b>B<\/b>\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08<\/b>Ph+ BCP-ALL<\/b>\uff09\u60a3\u8005
<\/b>\u6458\u8981\u7de8\u865f\uff1a<\/b>6513
\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u5feb\u901f\u53e3\u982d\u5831\u544a
\u5206\u6703\u5834\u6a19\u984c\uff1a<\/b>\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09
\u5831\u544a\u6642\u9593\uff1a<\/b>
2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09
2026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a<\/b>Elias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1<\/p>\n

Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
<\/b>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b>HQP1351<\/b>\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08<\/b>CP-CML<\/b>\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da
<\/b>\u6458\u8981\u7de8\u865f\uff1a<\/b>6510
\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u5feb\u901f\u53e3\u982d\u5831\u544a
\u5206\u6703\u5834\u6a19\u984c\uff1a<\/b>\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09
\u5831\u544a\u6642\u9593\uff1a<\/b>
2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09
2026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a<\/b>\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1<\/p>\n

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
<\/b>Alrizomadlin<\/b>\uff08<\/b>APG-115<\/b>\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08<\/b>APG-2575<\/b>\uff09\u6cbb\u7642\u5fa9\u767c<\/b>\/<\/b>\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08<\/b>RMS<\/b>\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08<\/b>STSs<\/b>\uff09\u5152\u7ae5\u60a3\u8005
<\/b>\u6458\u8981\u7de8\u865f\uff1a<\/b>10012
\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u5feb\u901f\u53e3\u982d\u5831\u544a
\u5206\u6703\u5834\u6a19\u984c\uff1a<\/b>\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09
\u5831\u544a\u6642\u9593\uff1a<\/b>
2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09
2026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a<\/b>\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3<\/p>\n

\u58c1\u5831\u5c55\u793a<\/u><\/b><\/p>\n

Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
<\/b>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b>HQP1351<\/b>\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08<\/b>SDH-<\/b>\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c
<\/b>\u6458\u8981\u7de8\u865f\uff1a<\/b>11539
\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u58c1\u5831\u5c55\u793a
\u5206\u6703\u5834\u6a19\u984c\uff1a<\/b>\u8089\u7624\uff08Sarcoma\uff09
\u5831\u544a\u6642\u9593\uff1a<\/b>
2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09
2026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a<\/b>\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3<\/p>\n

A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
<\/b>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b>HQP1351<\/b>\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684<\/b>III<\/b>\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684<\/b>POLARIS-2<\/b>\u8a66\u9a57
<\/b>\u6458\u8981\u7de8\u865f\uff1a<\/b>TPS6608
\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u58c1\u5831\u5c55\u793a
\u5206\u6703\u5834\u6a19\u984c\uff1a<\/b>\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09
\u5831\u544a\u6642\u9593\uff1a<\/b>
2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09
2026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a<\/b>Elias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1<\/p>\n

A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress
<\/b>\u5229\u6c99\u6258\u514b\u62c9\uff08<\/b>APG-2575<\/b>\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5<\/b>\/<\/b>\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08<\/b>CLL\/SLL<\/b>\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001<\/b>III<\/b>\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684<\/b>GLORA<\/b>\u8a66\u9a57
<\/b>\u6458\u8981\u7de8\u865f\uff1a<\/b>TPS7101
\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u58c1\u5831\u5c55\u793a
\u5206\u6703\u5834\u6a19\u984c\uff1a<\/b>\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09
\u5831\u544a\u6642\u9593\uff1a<\/b>
2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09
2026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a<\/b>Matthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662<\/p>\n

\u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/b><\/p>\n

\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002<\/p>\n

\u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae<\/sup>\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae<\/sup>\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae<\/sup>\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae<\/sup>\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae<\/sup>\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002<\/p>\n

\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae<\/sup>\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae<\/sup>\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae<\/sup>\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae<\/sup>\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae<\/sup>\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae<\/sup>\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae<\/sup>\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002<\/p>\n

\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/<\/a><\/p>\n

\u524d\u77bb\u6027\u8072\u660e<\/b><\/p>\n

\u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002<\/p>\n

\u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002<\/p>\n

\u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607…<\/p>\n","protected":false},"author":16,"featured_media":428740,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-428739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"\n\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u982d\u5831\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027B\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u6458\u8981\u7de8\u865f\uff1a6510\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin\uff08APG-115\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08STSs\uff09\u5152\u7ae5\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a10012\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 \u58c1\u5831\u5c55\u793a Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a11539\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8089\u7624\uff08Sarcoma\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684POLARIS-2\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS6608\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001III\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684GLORA\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS7101\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=428739\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u982d\u5831\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027B\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u6458\u8981\u7de8\u865f\uff1a6510\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin\uff08APG-115\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08STSs\uff09\u5152\u7ae5\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a10012\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 \u58c1\u5831\u5c55\u793a Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a11539\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8089\u7624\uff08Sarcoma\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684POLARIS-2\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS6608\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001III\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684GLORA\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS7101\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=428739\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-22T01:26:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1990\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\",\"datePublished\":\"2026-04-22T01:26:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739\"},\"wordCount\":265,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascentage_APAC_Logo-2.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739\",\"name\":\"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascentage_APAC_Logo-2.jpg\",\"datePublished\":\"2026-04-22T01:26:00+00:00\",\"description\":\"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e744\u670822\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u982d\u5831\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027B\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u6458\u8981\u7de8\u865f\uff1a6510\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\\\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin\uff08APG-115\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\\\/\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08STSs\uff09\u5152\u7ae5\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a10012\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 \u58c1\u5831\u5c55\u793a Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a11539\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8089\u7624\uff08Sarcoma\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684POLARIS-2\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS6608\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\\\/small lymphocytic lymphoma (CLL\\\/SLL): GLORA trial in progress\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001III\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684GLORA\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS7101\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\\\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\\\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\\\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\\\/\\\/ascentage.com\\\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascentage_APAC_Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascentage_APAC_Logo-2.jpg\",\"width\":400,\"height\":150},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=428739#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u982d\u5831\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027B\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u6458\u8981\u7de8\u865f\uff1a6510\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin\uff08APG-115\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08STSs\uff09\u5152\u7ae5\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a10012\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 \u58c1\u5831\u5c55\u793a Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a11539\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8089\u7624\uff08Sarcoma\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684POLARIS-2\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS6608\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001III\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684GLORA\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS7101\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=428739","og_locale":"zh_TW","og_type":"article","og_title":"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u982d\u5831\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027B\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u6458\u8981\u7de8\u865f\uff1a6510\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin\uff08APG-115\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08STSs\uff09\u5152\u7ae5\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a10012\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 \u58c1\u5831\u5c55\u793a Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a11539\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8089\u7624\uff08Sarcoma\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684POLARIS-2\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS6608\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001III\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684GLORA\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS7101\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=428739","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2026-04-22T01:26:00+00:00","og_image":[{"width":3000,"height":1990,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=428739"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a","datePublished":"2026-04-22T01:26:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=428739"},"wordCount":265,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-2.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=428739","url":"https:\/\/pingtungtimes.com.tw\/?p=428739","name":"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-2.jpg","datePublished":"2026-04-22T01:26:00+00:00","description":"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u7684\u516d\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u90782026\u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\uff08ASCO\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\u3002\u9019\u4e09\u500b\u91cd\u9ede\u54c1\u7a2e\u5206\u5225\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5291Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u6703\u662f\u5168\u7403\u816b\u7624\u9818\u57df\u6700\u91cd\u8981\u3001\u6700\u6b0a\u5a01\u7684\u5b78\u8853\u4ea4\u6d41\u76db\u6703\uff0c\u5c07\u5c55\u793a\u7576\u524d\u570b\u969b\u6700\u524d\u6cbf\u7684\u81e8\u5e8a\u816b\u7624\u5b78\u79d1\u7814\u6210\u679c\u548c\u816b\u7624\u6cbb\u7642\u6280\u8853\u3002\u672c\u5c46ASCO\u5e74\u6703\u5c07\u65bc5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u570b\u7576\u5730\u6642\u9593\uff09\u5728\u829d\u52a0\u54e5McCormick\u6703\u8b70\u4e2d\u5fc3\u4ee5\u7dda\u4e0a\u7dda\u4e0b\u7d50\u5408\u7684\u5f62\u5f0f\u8209\u8fa6\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u9019\u5c07\u662f\u4e9e\u76db\u91ab\u85e5\u9023\u7e8c\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u6703\uff0c\u5f88\u9ad8\u8208\u80fd\u5920\u53c8\u4e00\u6b21\u7ad9\u5728\u9019\u4e00\u570b\u969b\u9802\u5c16\u5b78\u8853\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u8207\u7814\u767c\u5be6\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u6709\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a\uff0c\u518d\u6b21\u5370\u8b49\u4e86\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u539f\u7814\u54c1\u7a2e\u81e8\u5e8a\u50f9\u503c\u7684\u9ad8\u5ea6\u8a8d\u53ef\u3002\u6211\u5011\u671f\u5f85\u5728\u6703\u8b70\u671f\u9593\u70ba\u5927\u5bb6\u5206\u4eab\u66f4\u70ba\u8a73\u5be6\u7684\u6578\u64da\uff0c\u4e26\u7e7c\u7e8c\u52a0\u901f\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u672c\u5c46ASCO\u5e74\u6703\u5c55\u793a\u7684\u81e8\u5e8a\u7814\u7a76\u9032\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u982d\u5831\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u6dcb\u7cfb\u6025\u8b8a\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027B\u7d30\u80de\u524d\u9ad4\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7dda\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u6458\u8981\u7de8\u865f\uff1a6510\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)Alrizomadlin\uff08APG-115\uff09\u55ae\u85e5\u6216\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u8f49\u79fb\u6027\u6a6b\u7d0b\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8edf\u7d44\u7e54\u8089\u7624\uff08STSs\uff09\u5152\u7ae5\u60a3\u8005\u6458\u8981\u7de8\u865f\uff1a10012\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u982d\u5831\u544a\u5206\u6703\u5834\u6a19\u984c\uff1a\u5152\u7ae5\u816b\u7624II\uff08Pediatric Oncology II\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f35\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u5152\u7ae5\u816b\u7624\u79d1\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 \u58c1\u5831\u5c55\u793a Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u816b\u7624\u60a3\u8005\u7684\u6700\u65b0\u81e8\u5e8a\u548c\u8f49\u5316\u7814\u7a76\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a11539\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8089\u7624\uff08Sarcoma\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u83ef\u5357\u816b\u7624\u5b78\u570b\u5bb6\u91cd\u9ede\u5be6\u9a57\u5ba4\uff0c\u816b\u7624\u91ab\u5b78\u5354\u540c\u5275\u65b0\u4e2d\u5fc3 A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7642\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684POLARIS-2\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS6608\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\u53ca\u540c\u7a2e\u7570\u9ad4\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u65e2\u5f80\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027\u3001\u96a8\u6a5f\u3001III\u671f\u6ce8\u518a\u81e8\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u9032\u884c\u4e2d\u7684GLORA\u8a66\u9a57\u6458\u8981\u7de8\u865f\uff1aTPS7101\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u5206\u6703\u5834\u6a19\u984c\uff1a\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09\u5831\u544a\u6642\u9593\uff1a2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff092026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u570b\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32MEA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=428739"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-2.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-2.jpg","width":400,"height":150},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=428739#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u30102026 ASCO\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u5176\u4e2d\u4e09\u9805\u7372\u5feb\u901f\u53e3\u982d\u5831\u544a"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/428739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=428739"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/428739\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/428740"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=428739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=428739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=428739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}